Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
All content for MyeConversations by Myeloma Australia is the property of Myeloma Australia and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
Part 2, Geoff chats further to Louise about his advocay roles, networking with his community, funding a research trial, advocating for himself and finding the services that he needs and finally self refection after his diagnosis of myeloma as a younger person.
MyeConversations by Myeloma Australia
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
